0001615219FALSE00016152192024-09-272024-09-27

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 20, 2024
SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-36812 46-5087339
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
     
2450 Holcombe Blvd.
Suite X
Houston, TX
 77021
(Address of principal executive offices) (Zip Code)
(832) 834-6992
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001
SLRX
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐


Item 5.07.
Submission of Matters to a Vote of Security Holders
On December 20, 2024, Salarius Pharmaceuticals, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of October 25, 2024, the record date for the Annual Meeting, there were 1,441,157 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 572,540, or 39.7%, were present in person or represented by proxy, which constituted a quorum.

At the Annual Meeting, the stockholders voted and: (1) re-elected each of the Company’s two nominees for Class III director; (2) approved, by non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting; and (3) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting.

Proposal 1. To elect two Class III directors to serve until the 2027 annual meeting or until their successors are duly elected and qualified:
Nominees
Votes For
Votes Against
Abstentions
Broker Non-Votes
Tess Burleson
141,974
12,711
2,127
415,728
Paul Lammers
145,485
9,196
2,131
415,728


Proposal 2. To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the Annual Meeting:
Votes For
Votes Against
Abstentions
Broker Non-Votes
135,949
18,637
2,226
415,728

Proposal 3. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024:
Votes For
Votes Against
Abstentions
496,239
59,576
16,725









SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SALARIUS PHARMACEUTICALS, INC.
Date: December 23, 2024
By:
/s/ Mark J. Rosenblum
Mark J. Rosenblum
Executive Vice President & Chief Financial Officer
v3.24.4
Cover Page
Sep. 27, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 20, 2024
Entity Registrant Name SALARIUS PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36812
Entity Tax Identification Number 46-5087339
Entity Address, Address Line Two Suite X
Entity Address, Address Line One 2450 Holcombe Blvd.
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77021
City Area Code 832
Local Phone Number 834-6992
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol SLRX
Entity Emerging Growth Company false
Entity Central Index Key 0001615219
Amendment Flag false
Salarius Pharmaceuticals (NASDAQ:SLRX)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025 Haga Click aquí para más Gráficas Salarius Pharmaceuticals.
Salarius Pharmaceuticals (NASDAQ:SLRX)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025 Haga Click aquí para más Gráficas Salarius Pharmaceuticals.